Friday August 17, 2018
Home Lead Story Qualcomm To A...

Qualcomm To Announce A New Chip Especially For Kids’ Smartwatches

The new chip would be smaller than the prior "Wear chips"

0
//
17
Qualcomm To Announce A New Chip Especially For Kids' Smartwatches
Qualcomm To Announce A New Chip Especially For Kids' Smartwatches. Pixabay
Republish
Reprint

Global chipmaker Qualcomm is likely to announce a new chip called “Snapdragon Wear 2500” that is especially designed for kids’ smartwatches.

The new chip would be smaller than the prior “Wear chips” and is supposed to provide slightly better battery life.

“The chip supports LTE, up to a 5-megapixel camera, location tracking and plenty of other sensors,” The Verge reported late on Tuesday.

“Kids’ watches are built to give kids the ability to keep learning and connecting with gadgets when they leave the house and find themselves in school, where they aren’t always beside a computer,” Pankaj Kedia, who leads wearables at Qualcomm, was quoted as saying.

However, “Snapdragon Wear 2500,” would not support Google’s smartwatch operating system (OS) “Wear OS”.

Instead, it would be paired with a custom version of Android that Qualcomm has built for kids’ watches called “Android for Kids” that would come preloaded with apps and games.

Snapdragon by qualcomm
Snapdragon by qualcomm. Flickr

Qualcomm has started providing the “Wear 2500” to hardware partners and Huawei could be among the first partners, the report said.

Qualcomm is also planning to launch its next general-purpose smartwatch chip meant for “Wear OS” watches “but there is no word on when that would happen as of now”.

Also read: Qualcomm, Microsoft offer ‘always connected’ PCs with smartphone features

The chipmaker announced its last processor for wearables, the “Snapdragon Wear 2100,” in February 2016. (IANS)

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

Marijuana Considered Safe to Cure Epilepsy in Kids

While the study's authors said the results were significant, they stressed that the purpose of this study was about safety not efficacy

0
Marijuana
Marijuana safe to treat epilepsy in kids: Study. Pixabay

Consuming a marijuana-based drug may be safe in treating children with severe epilepsy, results of a clinical trial has showed.

Following treatment with cannabidiol — a non-psychoactive compound found in marijuana — about one in five children were described as much or very much improved from their baseline, while around half reported none, or a very slight improvement, Xinhua news agency reported.

While the trial was conducted on a small group of children with severe epilepsy, it showed that the drug had a manageable side effect profile, but only showed extensive symptom relief for a brief number of patients.

The trial “involved the sickest children with epilepsy — children who are having seizures many times per day, who have been recently hospitalized for their epilepsy, and have failed on average about nine anti-epilepsy drugs before,” said lead author John Lawson, paediatric neurologist at Sydney’s Children’s Hospital.

“The main aim of the study was about safety. We found that there were a few safety concerns but overall those safety issues were very manageable and the drug overall was very safe for the majority,” he added.

Marijuana
Marijuana leaves. Pixabay

The study was published in the Medical Journal of Australia.

Although legally cannabis must be prescribed by a doctor, recent reports of cannabis derivatives being successful in treating children with epilepsy have led to a number of parents of sick children sourcing their own medical marijuana.

While the study’s authors said the results were significant, they stressed that the purpose of this study was about safety not efficacy.

Also Read: Oldest Known Rocks Evolved on Earth Are Result of Asteroids, Research Reveals

The US Food and Drug Administration had recently approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy — Lennox-Gastaut syndrome and Dravet syndrome — in patients two years of age and older. (IANS)